Cardiovascular Systems to Present at Three September Investor Conferences
September 02 2011 - 4:03PM
Business Wire
Cardiovascular Systems, Inc. (Nasdaq: CSII), a medical device
company developing and commercializing innovative, interventional
treatment systems for vascular and coronary disease, will present
at three upcoming conferences: the William Blair Life Sciences
Conference at the Intercontinental New York Barclay, the Robert W.
Baird Health Care Conference at the New York Palace, and the Sixth
Annual JMP Securities Health Care Conference at the St. Regis New
York. President and Chief Executive Officer David L. Martin and
Chief Financial Officer Laurence L. Betterley will provide an
overview of the company and its growth opportunities.
WHEN:
William Blair Life Sciences
Conference
Wednesday, Sept. 7; 10:50 a.m. ET Intercontinental New York Barclay
New York
Robert W. Baird Health Care
Conference
[Q&A format, no webcast] Wednesday, Sept. 7; 1:15 p.m. ET The
New York Palace New York
Sixth Annual JMP Securities Health Care
Conference
Tuesday, Sept. 27; 11 a.m. ET St. Regis New York New York
WEBCAST:
To listen to a live webcast of the
presentations at the William Blair Life Sciences Conference and
Sixth Annual JMP Securities Health Care Conference, go to the
investor information section of the company’s Web site,
www.csi360.com, and click on the respective webcast icon.
If you have any difficulty accessing the webcasts, please
contact
Mick Forgey: (612) 455-1789;
mforgey@psbpr.com
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
innovative solutions for treating vascular and coronary disease.
The company’s Stealth 360°™, Diamondback 360® and Predator 360® PAD
Systems treat calcified and fibrotic plaque in arterial vessels
throughout the leg in a few minutes of treatment time, and address
many of the limitations associated with existing surgical, catheter
and pharmacological treatment alternatives. The U.S. FDA granted
510(k) clearance for the use of the Diamondback 360° in August 2007
and for the Stealth 360° in March 2011. To date, more than 50,000
PAD procedures have been performed using CSI’s PAD systems in
leading institutions across the United States.
CSI has also commenced its ORBIT II Investigational Device
Exemption clinical trial to evaluate the safety and effectiveness
of its orbital technology in treating coronary arteries. The
coronary system is limited by federal law to investigational use
and is currently not commercially available in the United
States.
For more information, visit the company’s website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024